06.29.23 -- Identifying And Mitigating Absorption Risks In Early Drug Development

In this webinar, we discuss the role of solid form services in helping meet the accelerated timelines of the drug development life cycle and share examples of robust workflows for fast and thorough solid form screens. A case study reviews the polymorph screen of a late-stage API focusing on monotropic vs. enantiotropic polymorphs. We also highlight the crystallization process development of the lead form.

A comprehensive approach to evaluating drug molecules for the selection of a lead solid form and formulation can significantly accelerate development timelines and limit risks in later development. An integrated service package offers a combination of targeted testing and basic scientific principles to accelerate development of a preferred synthetic route, a progressible solid form, and a commercially viable formulation in early drug development.

Rapid and efficient development of drug candidates is increasingly important for pharmaceutical companies with accelerated timelines and funding constraints. Discover how PBPK models combined with custom and off-the shelf in vitro tools and solubility enhancement expertise can be used to identify and mitigate absorption risks in early drug development, reducing the need for drug product reformulation or repeated preclinical or clinical studies.

Explore the spray-drying process, including recent enhancements, an approach to scale-up programs, and recent developments to enable processing of extremely poorly soluble (aqueous and organic) molecules into amorphous dispersions for oral bioavailability enhancement. In this webinar, you can also learn heated solution processing approaches, novel solvents, and solution preparation techniques.